1996;93:15388 -15393. 29 Vansteenkiste JF, Zielinski , M,DahabrehIJ et al. Association of gene expression signature and clinical efficacy of MAGE -A3 antigen -specific cancer immunotherapeutic as adjuvant therapy in resected stage IB/II non -small cell lung cancer. Paper presented at: ASCO Annual Meeting; May 30 -June 3, 2008; Chicago, IL. 30 Butts CA, Socinski MA, Mitchell P et al. START: A phase III study of L -BLP25 cancer immunotherapy for unresectable stage III non -small cell lung cancer. J Clin Oncol 2013;31(suppl): abstr 7500. 31 Clinical Trials.gov. Cancer vaccine study for stage III, unresectable, non -small cell lung cancer (N SCLC) in the Asian population. Available at http://clinicaltrials.gov/ct2/results?term_NCT01015443&Search_Search 32 Clinical Trials.gov. BLP25liposome vaccine and bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB non -small cell lung cancer that cannot be removed by surgery. Available at: http://clinicaltrials.gov/ct2/results?term_NCT00828009&Search_Search. 33 Nemunaitis J, Nemunaitis M, Senzer N, et al : Phase II trial of Belagenpumatucel -L, a TGF -beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.Cancer Gene Ther 16:620 -624, 2009 . 34 Ramlau R, Quoix E, Rolski J et al. A phase II study of Tg4010 (Mva -Muc1 -Il2) in association with chem otherapy in patients with stage III/IV non small cell lung cancer. J Thorac Oncol 2008;3:735 –744. 35 Quoix E, Ramlau R, Westeel V et al. Therapeutic vaccination with TG4010 and first -line chemotherapy in advanced non -small -cell lung cancer: A controlled pha se 2B trial. Lancet Oncol 2011;12:1125 –1133. 36 Clinical Trials.gov. Phase IIB/III Of TG4010 immunotherapy In patients With stage IV non -small cell lung cancer. Available at: http://clinicaltrials.gov/ct2/results?term_NCT01383148&Search_Search. 37 Neninger Vinageras E, de la Torre A, Osorio Rodríguez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non -small -cell lung cancer. J Clin Oncol 2008;26:1452 – 1458. 38 Clinical Trials.gov. A randomized trial to study the safety and efficacy of EGF cancer vaccination in late - stage (IIIB/IV) non -small cell lung cancer patients. Available at: http://clinicaltrials.gov/ct2/results?term_NCT01444118&Search_Search 39 Le DT, Jaffee EM. Regulatory T -cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012;72;14:3439 -44. 40 Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauf fert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother.